GlassScriptPhysician profile
Bernadette Serafini
NPI 1497398606
$2,675.09
in general payments reported to CMS, 2019-2025
35 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 86% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,614 · 2022: $16.59 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $323.15 | 2025 | Aristada, Lybalvi |
| Amgen INC. | $318.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $249.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $224.79 | 2021-2025 | Cobenfy |
| Janssen Biotech, INC. | $158.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $139.52 | 2025 | Invega Sustenna, Invega Trinza |
| Novo Nordisk INC | $124.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.04 | 2025 | Caplyta |
| Indivior INC. | $75.71 | 2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $75.64 | 2021 | |
| Abbvie INC. | $71.33 | 2025 | |
| Glaxosmithkline, LLC. | $65.78 | 2021 | |
| Acceleron Pharma, INC. | $60.69 | 2021 | |
| Braeburn INC. | $56.32 | 2025 | Brixadi |
| Seagen INC. | $53.39 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $53.18 | 2021 | |
| Lilly USA, LLC | $43.16 | 2021 | |
| Array Biopharma INC | $42.63 | 2021 | |
| Merck Sharp & Dohme LLC | $41.47 | 2021 | |
| Daiichi Sankyo INC. | $38.61 | 2021 | |
| Epizyme, INC. | $37.60 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $36.53 | 2025 | Austedo Xr, Uzedy |
| Pfizer INC. | $32.96 | 2021 | |
| Kite Pharma, INC. | $32.59 | 2021 | |
| Genzyme Corporation | $31.70 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.13 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $20.93 | 2025 | Abilify Asimtufii |
| Pharmacyclics LLC, An Abbvie Company | $18.78 | 2021 | |
| Puma Biotechnology, INC. | $17.00 | 2021 | |
| Celgene Corporation | $16.59 | 2022 | |
| Incyte Corporation | $16.33 | 2021 | |
| Dendreon Pharmaceuticals LLC | $16.17 | 2021 | |
| Karyopharm Therapeutics INC. | $12.84 | 2021 | |
| Gilead Sciences, INC. | $12.68 | 2021 | |
| Genentech USA, INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Serafini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.